

14<sup>th</sup> August, 2025

**To,**  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C-1, Block G  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051.

**NSE Symbol: AAKAAR**  
**ISIN: INE1GYP01013**

Subject: Intimation under Regulation 30 of SEBI (LODR) Regulations – Exclusive Partnership with VM Corporation, Italy, for Launch of Exosome-Based Aesthetic and Regenerative Solutions in India.

Dear Sir/Madam,

Further to our letter dated 13.08.2025 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable provisions, we enclose herewith a press release titled: “Aakaar Medical Technologies to Bring Italy’s VM Corporation Exosome Breakthrough to India in November 2025”.

Yours truly,  
For Aakaar Medical Technologies Ltd.

Anoopkumar V. Pillai  
Company Secretary & Compliance Officer

Encl: Press Release as stated above.

## PRESS RELEASE

### **“Aakaar Medical Technologies to Bring Italy’s VM Corporation Exosome Breakthrough to India in November 2025**

**Exclusive partnership to introduce advanced hair, skin, and body contouring innovations powered by next generation synthetic and plant derived exosomes.**

Aakaar Medical Technologies Ltd has signed an exclusive agreement with VM Corporation (Italy) to launch its globally acclaimed exosome-based aesthetic and regenerative solutions in India. The phased rollout will commence in November 2025, starting with major metro cities before expanding nationwide.

#### **Launch Portfolio Highlights:**

- **VM EXO Signal Hair** – Advanced hair restoration therapy combining synthetic exosomes, PDRN, and plant stem cells.
- **V-Tech System** – Plant-based exosome platform for skin rejuvenation and dermal health optimisation.
- **Exo V Slim** – Innovative body contouring solution powered by synthetic exosomes and biomimetic peptides.

There is more in store beyond the above products.

VM Corporation is renowned for its integration of synthetic and plant-derived exosome technology with advanced actives like PDRN and biomimetic peptides, delivering next-generation regenerative science to the field of aesthetics. Its patented **SuperExo™** process uses supercritical CO<sub>2</sub> extraction to produce ultra-pure, standardised synthetic exosomes (~100 nm) with consistent clinical efficacy.

“With VM’s innovations, Indian practitioners will gain access to treatment modalities that have redefined **premium aesthetics globally**,” said **Dr Rahul Sawakhande**, CEO & Director, Aakaar Medical Technologies Ltd. “This collaboration strengthens our mission to deliver evidence-based, internationally benchmarked solutions to India’s rapidly growing premium aesthetics market.”

#### **Rollout & Training Initiatives**

The first phase will target India’s metro markets, supported by structured nationwide training programs for certified aesthetic physicians. Aakaar will also run patient awareness and education campaigns to promote safe, informed adoption of these breakthrough therapies.

#### **About VM Corporation**

Founded in 2016 by **Valerio Matanò**, VM Corporation is a pioneering Italian cosmeceutical company specialising in exosome technology for bio-regenerative aesthetic applications. The brand’s portfolio spans hair regeneration, skin rejuvenation, and body contouring—combining Italian design finesse with cutting-edge bioscience.

### **About Aakaar Medical Technologies Ltd**

Aakaar Medical Technologies is a leader in India's premium medical aesthetics sector, dedicated to introducing globally validated, science-backed innovations in skin, hair, and body treatments. Partnering with top international manufacturers, Aakaar aims to elevate clinical standards and expand treatment options for healthcare professionals and patients across India.

